Circulating adiponectin as a biomarker in renal cell carcinoma: a systematic review and meta-analysis.
Context: Metabolic imbalance in renal cell carcinoma (RCC) can lead to abnormal adiponectin levels. Objective: To evaluate circulating adiponectin as a detection or predictive marker for RCC. Methods: A comprehensive literature search and meta-analysis was performed on studies reporting circulating adiponectin levels and RCC. The meta-analysis was performed using RevMan. Results: Seven studies compared the circulating adiponection levels between RCC cases and controls. Adiponectin level was significantly lower in RCC cases compared to controls at pre-diagnosis and pre-operative time-points. RCC stage, grade and subtype did not affect adiponectin levels. Conclusion: Low circulating adiponectin could be a predictive or risk factor for RCC.
['Yap|Ning Yi|NY|', 'Yap|Foo Ngan|FN|', 'Perumal|Komathi|K|', 'Rajandram|Retnagowri|R|']
D052242:Adiponectin D014408:Biomarkers, Tumor D002292:Carcinoma, Renal Cell D016022:Case-Control Studies D015870:Gene Expression D006801:Humans D007680:Kidney Neoplasms D060787:Neoplasm Grading D009367:Neoplasm Staging D012307:Risk Factors
circulating Adiponectin renal cell carcinoma adipokine obesity